Third Harmonic Bio Stock (NASDAQ:THRD)

Forecast Revenue Ownership Financials Chart

Previous Close

$5.29

52W Range

$5.07 - $16.94

50D Avg

$10.24

200D Avg

$12.07

Market Cap

$234.30M

Avg Vol (3M)

$240.31K

Beta

2.86

Div Yield

THRD Company Profile

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 14, 2022

Website

THRD Performance

THRD Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-43.95M	$-37.71M	$-19.00M
Net Income	$-30.82M	$-37.71M	$-29.61M
EBITDA	$-43.92M	$-37.71M	$-19.00M
Basic EPS	$-0.78	$-2.81	$-1.13
Diluted EPS	$-0.78	$-2.81	$-1.13

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
NUVB	Nuvation Bio Inc.
RVMD	Revolution Medicines, Inc.
RLYB	Rallybio Corporation
SNSE	Sensei Biotherapeutics, Inc.
NXTC	NextCure, Inc.
PMVP	PMV Pharmaceuticals, Inc.
HOWL	Werewolf Therapeutics, Inc.
PASG	Passage Bio, Inc.
GLUE	Monte Rosa Therapeutics, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
EWTX	Edgewise Therapeutics, Inc.
CGEM	Cullinan Oncology, Inc.